CTOs on the Move

Harken Health

www.harkenhealth.com

 
Harken Health is a new kind of health care company that unites relationship-based primary care with a range of competitively priced insurance plan options. Our care approach is rooted in the values of a simpler time when the doctor-patient relationship mattered. Harken Health Care Teams are empowered with the time to listen and build authentic, compassionate, trusting relationships with members. Our model enables us to remove many of the barriers that often get in the way of delivering exceptional care. Strong relationships and a home base for primary care have been shown to improve patient satisfaction and lower overall medical ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Peter Vladimirov
Chief Technology Officer Profile

Similar Companies

IMD - Innovative Medical Devices

IMD - Innovative Medical Devices is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Grason Stadler

Grason Stadler is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Santera Rehabilitation Inc

Santera Rehabilitation Inc is a Bristol, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Andrus

Andrus nurtures hope in children by providing care that empowers them to succeed and by promoting innovation and standards of excellence in the care of children in our community and beyond. Andrus nurtures social and emotional well-being in children and their families by delivering a broad range of vital services and by providing research, training and innovative program models that promote standards of excellence for professional performance in and beyond our service community.  

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.